New drug combo aims to stop deadly esophageal cancer from coming back
NCT ID NCT05480384
Summary
This study tests whether a combination of two drugs (trastuzumab deruxtecan and nivolumab) given for one year after surgery can help prevent cancer from returning in patients with HER2-positive esophageal or gastroesophageal junction cancer. The treatment is for patients who have already completed chemotherapy, radiation, and surgery but still have some cancer risk. Researchers want to see if this drug combination is safe and effective at keeping patients cancer-free.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Weill Cornell Medicine/New York-Presbyterian
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.